|
Volumn 66, Issue 1, 2014, Pages 179-180
|
Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABIRATERONE ACETATE;
DOCETAXEL;
PROSTATE SPECIFIC ANTIGEN;
17-(3-PYRIDYL)-5,16-ANDROSTADIEN-3BETA-ACETATE;
ANDROSTANE DERIVATIVE;
ANTINEOPLASTIC AGENT;
DRUG RESPONSE;
DRUG TREATMENT FAILURE;
HUMAN;
LETTER;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
WITHDRAWAL SYNDROME;
AGED;
BLOOD;
BONE TUMOR;
CASE REPORT;
LYMPH NODE METASTASIS;
MALE;
PATHOLOGY;
PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;
RETREATMENT;
SCINTISCANNING;
SECONDARY;
AGED;
ANDROSTADIENES;
ANTINEOPLASTIC AGENTS;
BONE NEOPLASMS;
HUMANS;
LYMPHATIC METASTASIS;
MALE;
POSITRON-EMISSION TOMOGRAPHY;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;
RETREATMENT;
|
EID: 84902082468
PISSN: 03022838
EISSN: 18737560
Source Type: Journal
DOI: 10.1016/j.eururo.2014.03.014 Document Type: Letter |
Times cited : (4)
|
References (5)
|